登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07678957,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:仅女性
登记记录的入选字段
Toxicities from prior antitumor therapy have recovered to ≤Grade 1 per NCI-CTCAE v6.0;
入选标准第 9 条
Received surgery, curative radiotherapy, immunotherapy, or other systemic anti-tumor therapies within 4 weeks prior to the first dose;
排除标准第 1 条
Prior treatment with anti-HER2 therapy;
排除标准第 3 条
Prior anthracycline treatment with a cumulative equivalent dose of doxorubicin > 360 mg/m²;
排除标准第 14 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
入选标准第 8 条
Have at least one measurable target lesion per RECIST v1.1 criteria;
入选标准第 7 条
Diagnosis of another primary malignancy within 5 years prior to the first dose;
排除标准第 9 条
Positive for human immunodeficiency virus (HIV) antibody, active hepatitis B virus (HBV) infection, liver cirrhosis, or hepatitis C virus (HCV) infection;
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07678957,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent form and agree to comply with the protocol requirements; Female patients aged ≥18 years and ≤75 years at the time of signing the informed consent form; Life expectancy ≥12 weeks; Locally recurrent or metastatic breast cancer that is hormone receptor (HR)-positive and HER2-low expressing; Provide adequate and recent tumor tissue specimens for central laboratory testing of HER2, HR, and other biomarkers as required; Meet the prior treatment requirements as specified in the protocol; Have at least one measurable target lesion per RECIST v1.1 criteria; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Toxicities from prior antitumor therapy have recovered to ≤Grade 1 per NCI-CTCAE v6.0; Adequate organ function as defined in the protocol; For premenopausal women of childbearing potential, a serum pregnancy test must be performed within 7 days prior to the start of treatment and must be negative; patients must not be breastfeeding. All enrolled patients (both male and female) must use adequate and highly effective contraceptive measures throughout the entire treatment period and for 7 months after the last dose of study treatment.排除标准:Exclusion Criteria:
Received surgery, curative radiotherapy, immunotherapy, or other systemic anti-tumor therapies within 4 weeks prior to the first dose; Intolerance to the control drug or presence of other contraindications to the control drug; Prior treatment with anti-HER2 therapy; Prior treatment with an ADC (antibody-drug conjugate) using a camptothecin derivative as the payload; History of severe cardiovascular or cerebrovascular disease within 6 months prior to screening; Concurrent pulmonary disease resulting in severely impaired lung function; History of ILD/interstitial lung disease requiring corticosteroid therapy, etc.; QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias; Diagnosis of another primary malignancy within 5 years prior to the first dose; Uncontrolled hypertension; Active central nervous system (CNS) metastases; History of severe allergic reactions to any excipient or component of the investigational drug; History of autologous or allogeneic stem cell transplantation or organ transplantation; Prior anthracycline treatment with a cumulative equivalent dose of doxorubicin > 360 mg/m²; Positive for human immunodeficiency virus (HIV) antibody, active hepatitis B virus (HBV) infection, liver cirrhosis, or hepatitis C virus (HCV) infection; Occurrence of severe infection within 4 weeks prior to the first dose of the investigational drug; Presence of large-volume serous cavity effusion, or serous cavity effusion with significant symptoms; Presence of lymphangitic carcinomatosis; Receiving systemic corticosteroid therapy at a dose of > 10 mg/day prednisone or equivalent prior to randomization; Presence of severe neurological or psychiatric disorders; Clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent; Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.; Planned vaccination or receipt of live vaccine within 28 days prior to the first dose; Presence of other severe physical conditions, laboratory abnormalities, or poor compliance, which may increase the risk of participating in the study, interfere with the study results, or render the patient unsuitable for enrollment as judged by the investigator.
引自 ClinicalTrials.gov, NCT07678957, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07678957,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。